Calliditas Therapeutics AB ADR (CALT) Social Stream
CALLIDITAS THERAPEUTICS AB (CALT) Price Targets From Analysts
Use the tables below to see what analysts covering CALLIDITAS THERAPEUTICS AB think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-19 | 4 | $55 | $48 | $51.75 | $25.655 | 101.72% |
| 2021-12-15 | 4 | $56 | $48 | $52 | $25.655 | 102.69% |
| 2021-12-17 | 4 | $59 | $52 | $55.5 | $25.655 | 116.33% |
| 2022-01-13 | 4 | $62 | $55 | $58 | $25.655 | 126.08% |
| 2022-02-24 | 3 | $59 | $55 | $56.666 | $25.655 | 120.88% |
| 2022-11-14 | 3 | $60 | $55 | $57 | $25.655 | 122.18% |
| 2023-01-03 | 3 | $57 | $55 | $56 | $25.655 | 118.28% |
| 2023-02-23 | 4 | $57 | $55 | $56 | $25.655 | 118.28% |
| 2023-02-24 | 4 | $79 | $53 | $60.75 | $25.655 | 136.8% |
| 2023-05-16 | 6 | $79 | $18 | $52.4 | $25.655 | 104.25% |
| 2023-08-17 | 6 | $79 | $18 | $51.833 | $25.655 | 102.04% |
| 2023-11-09 | 6 | $79 | $18 | $50.166 | $25.655 | 95.54% |
| 2023-12-20 | 6 | $55 | $18 | $40.833 | $25.655 | 59.16% |
The Trend in the Analyst Price Target
CALT's average price target has moved down $12.83 over the prior 170 days.
CALT reports an average of 180.25% for its upside potential over the past 43 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-02-23 | 4 | 57 | 55 | 56.000 | 19.99 | 180.14% |
| 2023-05-16 | 6 | 79 | 18 | 52.200 | 21.17 | 146.58% |
| 2023-05-16 | 5 | 79 | 18 | 52.400 | 21.17 | 147.52% |
| 2023-08-21 | 6 | 79 | 18 | 50.166 | 17.44 | 187.65% |
| 2023-11-09 | 6 | 55 | 18 | 40.833 | 16.80 | 143.05% |
CALT Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.33 | 5 | 0 | 1 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
Over the past 26 weeks, CALT's average broker recommendation rating improved by 0.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In the context of all US stocks, CALLIDITAS THERAPEUTICS AB's variance in analysts' estimates is lower than -697.48% of them.
- CALT has a higher number of analysts covering the stock than 300.76% of all US stocks.
- CALT has a greater average analyst price target than 1570.12% of stocks in the small market cap category.
- In terms of how CALLIDITAS THERAPEUTICS AB fares relative to stocks in the small market cap category, note that its upside potential (average analyst target price relative to current price) is greater than 970.34% of that group.
Stocks similar to CALLIDITAS THERAPEUTICS AB in the Pharmaceutical Products industry regarding analyst recommendations and price targets are RNA, GBIO, and RPTX.
View All Top Stocks by Price Target
Is CALT a Buy, Hold or Sell? See the POWR Ratings now!